Research compounds
Adrenomedullin
ADM, AM
Adrenomedullin is a 52-amino-acid vasodilator peptide originally isolated from phaeochromocytoma tissue, with roles in vascular tone, endothelial barrier function and sepsis. It is not approved as a therapy, though an antibody targeting it has been in sepsis trials.
Also known as: adrecizumab target
- Status
- Adrenomedullin is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 22 minutes.
- How it's taken
- Intravenous infusion in the research setting
- Mechanism
- Other
How Adrenomedullin works
Adrenomedullin signals through the calcitonin receptor-like receptor with RAMP2 or RAMP3 accessory proteins, producing cAMP-mediated vasodilation and — importantly — stabilisation of the endothelial barrier. In sepsis this creates a therapeutic paradox: circulating adrenomedullin contributes to pathological vasodilation and shock, while interstitial adrenomedullin protects the vascular barrier.
What research has looked at
- Its dual role in vascular tone and endothelial barrier integrity makes it mechanistically distinctive among vasoactive peptides.
- Adrenomedullin levels are an established prognostic biomarker in sepsis and heart failure.
- Adrecizumab, a non-neutralising antibody designed to shift adrenomedullin from the circulation into the interstitium, has been trialled in septic shock on the basis of that compartment paradox — an unusually sophisticated therapeutic strategy.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- No adrenomedullin-based therapy has been approved. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Administering adrenomedullin causes hypotension and reflex tachycardia, which is precisely the problem in the shock states where it is of interest.
- Its compartment-dependent effects mean the direction of benefit from any intervention is not intuitive and depends on where the peptide ends up.
- It is cleared within minutes.
Sources
- PubMed research on adrenomedullin adrecizumab septic shock endothelial barrier · NIH · National Library of Medicine
- DrugBank record for adrenomedullin · DrugBank
- Active clinical trials for adrenomedullin · U.S. National Library of Medicine
Track Adrenomedullin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Adrenomedullin FAQ
What is Adrenomedullin?
Adrenomedullin is a 52-amino-acid vasodilator peptide originally isolated from phaeochromocytoma tissue, with roles in vascular tone, endothelial barrier function and sepsis. It is not approved as a therapy, though an antibody targeting it has been in sepsis trials.
How does Adrenomedullin work?
Adrenomedullin signals through the calcitonin receptor-like receptor with RAMP2 or RAMP3 accessory proteins, producing cAMP-mediated vasodilation and — importantly — stabilisation of the endothelial barrier. In sepsis this creates a therapeutic paradox: circulating adrenomedullin contributes to pathological vasodilation and shock, while interstitial adrenomedullin protects the vascular barrier.
Is Adrenomedullin FDA approved?
No. Adrenomedullin is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Adrenomedullin?
Reported half-life: Approximately 22 minutes.
How is Adrenomedullin taken?
Intravenous infusion in the research setting.
What side effects have been reported with Adrenomedullin?
Reported in the sources: No adrenomedullin-based therapy has been approved. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Administering adrenomedullin causes hypotension and reflex tachycardia, which is precisely the problem in the shock states where it is of interest; Its compartment-dependent effects mean the direction of benefit from any intervention is not intuitive and depends on where the peptide ends up; It is cleared within minutes.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.